Aquestive Therapeutics, Inc.
AQST
$6.45
$0.304.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.32% | -24.38% | 5.29% | 13.80% | 22.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.32% | -24.38% | 5.29% | 13.80% | 22.56% |
| Cost of Revenue | -4.39% | -6.64% | -16.35% | -14.20% | -15.97% |
| Gross Profit | -36.00% | -32.54% | 19.58% | 33.40% | 53.63% |
| SG&A Expenses | 44.18% | 53.70% | 67.40% | 58.05% | 28.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.98% | 31.52% | 34.46% | 34.48% | 14.35% |
| Operating Income | -164.37% | -246.29% | -111.67% | -103.75% | 3.66% |
| Income Before Tax | -96.61% | -152.57% | -90.22% | -479.03% | -193.24% |
| Income Tax Expenses | -113.86% | 64.10% | -105.71% | -105.71% | -29.86% |
| Earnings from Continuing Operations | -96.00% | -152.89% | -88.55% | -460.83% | -190.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.00% | -152.89% | -88.55% | -460.83% | -190.59% |
| EBIT | -164.37% | -246.29% | -111.67% | -103.75% | 3.66% |
| EBITDA | -175.49% | -270.86% | -122.56% | -118.72% | 2.07% |
| EPS Basic | -55.71% | -93.41% | -36.54% | -378.65% | -110.44% |
| Normalized Basic EPS | -52.98% | -88.88% | -44.07% | -122.00% | -26.01% |
| EPS Diluted | -55.71% | -93.41% | -36.54% | -261.66% | -79.78% |
| Normalized Diluted EPS | -52.98% | -88.88% | -44.07% | -122.31% | -26.12% |
| Average Basic Shares Outstanding | 22.86% | 27.23% | 40.27% | 41.63% | 39.11% |
| Average Diluted Shares Outstanding | 22.86% | 27.23% | 40.27% | 31.85% | 29.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |